$MCRB
Seres Therapeutics Inc
PRICE
$3.19 -
Extented Hours
VOLUME
854,637
DAY RANGE
2.97 - 3.22
52 WEEK
2.91 - 25.06
Key Metrics
Market Cap
276.69 M
Beta
1.20
Avg. Volume
883.41 K
Shares Outstanding
92.23 M
Yield
0%
Public Float
0
Next Earnings Date
2022-08-02
Next Dividend Date
Company Information
Seres Therapeutics, Inc., is a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres' SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres' SER-287 program has obtained Fast Track and Orphan Drug designations from the FDA and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres is evaluating SER-301 in a Phase 1b study in patients with ulcerative colitis, and SER-155 to prevent mortality due to gastrointestinal infections, bacteremia and graft versus host disease.
CEO: Eric Shaff
Website: www.serestherapeutics.com
HQ: 200 Sidney St Cambridge, 02139-4218 Massachusetts
Related News
